New device aims to catch debris during heart procedure, reduce stroke risk

NCT ID NCT07276711

Recruiting now Disease control Sponsor: EmStop Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new device called EmStop that captures debris during a heart valve replacement procedure (TAVR) for aortic stenosis. About 663 people will be randomly assigned to receive either the EmStop device or a standard device. The goal is to see if EmStop reduces the risk of major heart and brain events, like stroke, within 30 days after the procedure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: EmStop Embolic Protection System (device)
What this could lead to: If successful, this device could make TAVR safer by reducing the risk of stroke and kidney damage from debris.
What could go wrong: This is an early-stage trial with 663 participants, and the device may not significantly reduce complications compared to existing options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AORTIC STENOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Aortic Valve Disease aortic valve disorder aortic valve stenosis stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTIC STENOSIS AORTIC VALVE DISEASE AORTIC VALVE STENOSIS

Contacts and locations

Locations

Mission Health
RECRUITING

Asheville, North Carolina, 28801, United States
Monument Health Heart and Vascular Institute
RECRUITING

Rapid City, South Dakota, 57701, United States
Ochsner Medical Center
RECRUITING

New Orleans, Louisiana, 70121, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.